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Background: Chemotherapy-induced nausea and vomiting
can adversely affect patients’ health and quality of life.
Guidelines recommend prophylactic antiemetic regimens
according to the emetogenic potential of anti-tumor thera-
pies. However, these recommendations are not for patients
receiving high-dose myeloablative regimens prior to stem
cell transplant (SCT). Current guidelines do not recommend
a speciﬁc antiemetic regimen for patients receiving high-
dose chemotherapy prior to SCT due to a lack of evidence. At
VCUHS, the standard of care in patients receiving high-dose
melphalan prior to SCT was an antiemetic regimen con-
sisting of ondansetron + dexamethasone. Due to perceived
poor nausea and vomiting control, the standard of care was
changed in August of 2012 to a three-drug regimen con-
taining aprepitant. Following this change in practice, this
project was undertaken for the primary objective of deter-
mining the effectiveness of an antiemetic regimen con-
taining aprepitant compared to the previous standard of
care in patients receiving high-dose melphalan prior to
autologous SCT.
Methods: This retrospective observational review compared
patients who received the previous antiemetic standard of
care to those who received the three-drug regimen con-
taining aprepitant prior to autologous SCT with high-dose
melphalan conditioning at VCUHS between April 2010
and April 2013. The primary outcome measure was
overall nausea control (NC), deﬁned as no episodes of
documented emesis and  2 uses of rescue antiemetics in
the overall phase (D-2 to D+2) with no additional scheduled
antiemetics.
Results: 114 patients were included in the analysis. The rate
of overall NC was not signiﬁcantly different between the
two groups [treatment difference -1%, 95% CI -19 to 18].
However, the mean number of episodes of emesis was
signiﬁcantly lower in the aprepitant group than in the
control group in the acute (0 vs. 0.2, p ¼ 0.012), delayed
(0.3 vs. 1.3, p < 0.001), and overall period (0.3 vs. 1.4, p <
0.001). Also, fewer patients in the aprepitant group
required additional scheduled antiemetics (3% vs. 36%, p ¼
0.011) than patients in the control group. There were no
signiﬁcant differences in length of stay or time to neutro-
phil engraftment.
Conclusions: The addition of aprepitant failed to demon-
strate a statistically signiﬁcant beneﬁt in terms of overall
NC when compared to the previous antiemetic standard of
care in patients receiving high-dose melphalan prior to
autologous SCT. This lack of beneﬁt and lower than ex-
pected rates of overall NC were attributed to aggressive
pre-emptive rescue antiemetic use and additional doses of
scheduled ondansetron in the control group. However, this
analysis did ﬁnd that aprepitant reduces episodes of
emesis and use of additional scheduled antiemetics in
patients receiving high-dose melphalan prior to autolo-
gous SCT.452
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Introduction: Cytomegalovirus (CMV) infection can increase
the morbidity and mortality associated with allogeneic he-
matopoietic stem cell transplantation (HSCT). Due to a higher
degree of immunosuppression, haploidentical transplants
can be at an increased risk of viral infections, particularly
CMV.
Methods: In a retrospective review of haploidentical HSCT
patients, we compared a traditional antiviral prophylaxis
regimen with an intensiﬁed approach to determine whether
a more intensive strategy could decrease rates of CMV
reactivation. CMV reactivation rates between the two groups
were compared using Fischer’s exact test. Themedian time to
reactivation and engraftment were compared using the
Mann-Whitney U test. A Kaplan-Meier survival curve was
utilized for non-relapse mortality (NRM) and patient groups
were compared using the log-rank statistic.
Results: A total of 84 patients underwent haploidentical
HSCT from 3/2009 through 5/2013. Patients were excluded
due to the following: donor and recipient negative serostatus
(n¼7), CMV reactivation prior to day 0 (n¼3), second trans-
plant (n¼7), or use of other antiviral therapy during the ﬁrst
100 days for non-CMV infections (n¼4). The median follow
up for the remaining 63 patients was 295 days (range 7 e
1473). Patients received valacyclovir 500 mg orally daily
starting on day -1 (n¼26) or either valganciclovir 900 mg
orally twice a day or ganciclovir 5 mg/kg IV twice daily from
admission through day -2 followed by traditional or high
dose valacyclovir (n¼37). Upon CMV reactivation, preemp-
tive therapy was commenced in both groups. Baseline char-
acteristics were similar between the groups and all patients
received conditioning chemotherapy with ﬂudarabine and
melphalan +/- TBI 200 cGy or thiotepa, as previously
described. CMV reactivation prior to day 100 was lower in
the intensive strategy group compared to the traditional
strategy although not signiﬁcant (68% vs. 85%; p¼ 0.15).
Median time to CMV reactivation was not signiﬁcant be-
tween the traditional and intensive groups (31 days vs. 33
days; p ¼0.13). A difference in median time to engraftment
was not evident (18 days vs. 18 days; p¼0.72). One patient in
each group had primary graft failure. Non-relapse mortality
did not differ between the groups [HR 0.75 (0.25, 2.22);
p¼0.6].
Conclusion: A trend towards decreased CMV reactivation and
longer time to reactivation was seen with an active CMV
regimen prior to day 0 in haploidentical HSCT patients.
Although currently underpowered, data collection is ongoing.453
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